Trials / Completed
CompletedNCT03133637
Ceftriaxone and Jaundice in Neonates
Effect of Ceftriaxone on Neonatal Jaundice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 3 Days – 7 Days
- Healthy volunteers
- Not accepted
Summary
Ceftriaxone is an antibiotic often used for the management of sepsis. Neonates commonly have jaundice during the first postnatal week. Ceftriaxone will be given as standard of care for sepsis and investigators will observe the effect on jaundice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ceftriaxone | Eligible infants will receive ceftriaxone as standard of care for sepsis |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2019-08-31
- Completion
- 2019-08-31
- First posted
- 2017-04-28
- Last updated
- 2021-04-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03133637. Inclusion in this directory is not an endorsement.